Navigation Links
Genencor Launches First Ever Commercial Enzyme Product for Cellulosic Ethanol
Date:10/15/2007

Accellerase(TM) 1000 is launched at the Cellulosic Ethanol Summit in

Washington, DC

ROCHESTER, N.Y., Oct. 15 /PRNewswire/ -- Genencor, a division of Danisco A/S, today announced a new product, Accellerase(TM) 1000, the first ever commercially available biomass enzyme developed specifically for second generation biorefineries. Accellerase(TM) 1000 contains a potent complex of enzymes that reduces complex lignocellulosic biomass into fermentable sugars -- an indispensable step for the production of cellulosic ethanol.

Genencor has been developing its biomass enzymes for well over 10 years. The effort was partially supported by contracts with the US Department of Energy's (DOE) National Renewable Energy Laboratory (NREL). Commercial interest in second generation biorefineries, driven in part by government policies to reduce the emission of greenhouse gases and increase energy independence, has accelerated over the past two years in the USA and around the world. Accellerase(TM) 1000 will fill a large unmet need for reliable biomass enzyme supply to pilot and demonstration plant developers who are actively working on process development, scale up and integration. Accellerase(TM) 1000 is the first in what the company expects to be a family of products tailored to different biomass feedstocks and system conditions. The key features that are expected to be important at commercial scale are already built into this first product.

"The biofuels industry is at an inflection point with the development of cellulosic ethanol plants at the pilot and demonstration scale," said Jack Huttner, vice president of biorefinery business development. "Every biorefinery developer needs to know how enzymes will work in their system. This product aims to address that need and to start a dialogue with potential partners about customized solutions and supply at the industrial scale."

"Enzymes, such as those developed by Genencor, will serve as catalysts to the commercial-scale viability of cellulosic ethanol, a clean source of energy to help meet President Bush's goal of reducing our reliance on oil," DOE Assistant Secretary Andy Karsner said. "Ethanol from new feed stocks will not only give America more efficient fuel options to help transform our transportation sector, but increasing its use will help reduce greenhouse gas emissions."

Product information and technical applications information is available on the website http://www.genencor.com/cellulosicethanol. Accellerase(TM) 1000 will be available for sample and sale immediately. Call the customer relations numbers below or email customer_relations@genencor.com to place your order.

Europe/Africa /Middle East: +31 71 5686 168

United States and Canada: +1 800 847 5311

Asia/Pacific: +1 65 6511 5600

Latin America: +54 11 5199 9550

HIGHLIGHTS OF ACCELLERASE BENEFITS

-- Enhanced saccharification performance on a variety of feedstocks.

-- Ability to operate in simultaneous saccharification and fermentation

(SSF) processes, two step sequential hydrolysis and fermentation (SHF)

processes or hybrids of the two.

-- High beta-glucosidase activity to minimize residual cellobiose, which

may lead to a higher saccharification and ultimately to a faster

ethanol fermentation. Yields may also be improved.

-- Unclarified product. The remaining nutrients from enzyme production

are available to the yeast in addition to the fermentable sugars

produced by saccharification.

-- Minimal formulation to ensure that enzyme formulation chemicals do not

interfere with saccharification carbohydrate profile analysis or

subsequent yeast fermentation.

About Genencor

Genencor, a division of Danisco A/S, is a leader in the industrial biotechnology sector. In more than 40 countries, Genencor's 1,500 employees develop and market innovative enzymes and biobased solutions to improve the performance and reduce the environmental impact of a wide variety of industries, from laundry detergents to transportation fuels. Genencor also develops and produces enzymes for the food, beverage and animal nutrition industries, which are sold under the Danisco brand. In partnership with our customers, technology leaders and other stakeholders, Genencor's cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as one of the leaders in the emerging biobased economy.


'/>"/>
SOURCE Genencor
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):